{"prompt": "['Alliance A221701', 'Alliance study ID (i.e., \"A221701\")', 'Alliance patient ID number (e.g., \"999999\")', 'Patient initials (e.g., \"L,FM\")', 'Institution name', 'Name and telephone number of treating physician', 'Name and contact information of person requesting the unblinding procedure', 'Name and contact information of person to inform of treatment assignment', 'Reason for emergency unblinding', 'Please remember that emergency unblinding request may be authorized only by an', 'Alliance Executive Officer, and emergency unblinding applies only if unblinding', 'would influence management of the medical situation. After the Executive Officer', 'deems unblinding is warranted, the treatment assignment will be provided to the', 'contact person at the treating site.', '30', 'NCI version date 8/14/2020', 'Update #03']['Alliance A221701', '9.0', 'ADVERSE Events', 'The prompt reporting of adverse events is the responsibility of each investigator engaged in clinical', 'research, as required by Federal Regulations. Adverse events must be described and graded using the', \"terminology and grading categories defined in the NCI's Common Terminology Criteria for Adverse\", 'Events', '(CTCAE),', 'Version', '5.0.', 'The', 'CTCAE', 'is', 'available', 'at', 'Attribution to protocol', 'treatment for each adverse event must be determined by the investigator and reported on the required', 'forms. Please refer the NCI Guidelines: Adverse Event Reporting Requirements for further details', 'on AE reporting procedures.', 'NOTE: PRO-CTCAE data should not be used for determining attribution, or reporting of adverse', 'events.', '9.1', 'Routine Adverse Event Reporting', 'Adverse event data collection and reporting, which are required as part of every clinical trial are', 'done to ensure the safety of patients enrolled in the studies as well as those who will enroll in', 'future studies using similar agents. Adverse events are reported in a routine manner at scheduled', 'times according to the study calendar in Section 5.0. For this trial, the Adverse Event Solicited', 'form is used for routine AE reporting in Rave.', 'Solicited Adverse Events: The following adverse events are considered \"expected\" and their', 'presence/absence should be solicited, and severity graded, at baseline and weekly throughout', 'the eight weeks of treatment by CTCAE, PRO-CTCAE or both.', 'CTCAE v5.0 Term', 'PRO-CTCAE v1.0 Term', 'CTCAE v5.0 System Organ Class (SOC)', 'Mucositis oral', 'Mouth/throat sore', 'Gastrointestinal Disorders', 'Oral pain', 'Mouth/throat sore', 'Gastrointestinal Disorders', 'Insomnia', 'Sleep', 'Psychiatric Disorders', 'Fatigue', 'Fatigue', 'General Disorders and administration site', 'conditions', 'Mucosal infection', 'N/A', 'Infections and Infestations', 'Hyperglycemia', 'N/A', 'Metabolism and Nutrition Disorders', 'Irritability', 'N/A', 'Psychiatric Disorders', '31', 'NCI version date 8/14/2020', 'Update #03']['Alliance A221701', '9.2', 'CTCAE Routine Reporting Requirements', 'In addition to the solicited adverse events listed in Section 9.1, the following table outlines the', 'combinations of time points, grades and attributions of AEs that require routine reporting to the', 'Alliance Statistics and Data Center. Questions about routine reporting should be directed to the', 'Data Manager.', 'Combinations of CTCAE Grade & Attribution Required for Routine AE Data Submission on', 'Case Report Forms (CRFs)', 'Attribution', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Grade 5', 'Unrelated', 'a', 'a', 'a', 'Unlikely', 'a', 'a', 'a', 'Possible', 'a', 'a, b', 'a, b', 'a, b', 'Probable', 'a', 'a, b', 'a, b', 'a, b', 'Definite', 'a', 'a, b', 'a, b', 'a, b', 'a)', 'Adverse Events: Other CRF - Applies to AEs occurring between registration and within 30', \"days of the patient's last treatment date, or as part of the Clinical Follow-Up Phase.\", '9.3', 'Expedited Adverse Event Reporting (CTEP-AERS)', 'Investigators are required by Federal Regulations to report serious adverse events as defined in', 'the table below. Alliance investigators are required to notify the Investigational Drug Branch', '(IDB), the Alliance Central Protocol Operations Program, the Study Chair, and their', 'Institutional Review Board if a patient has a reportable serious adverse event. The descriptions', 'and grading scales found in the NCI Common Terminology Criteria for Adverse Events', '(CTCAE) version 5 will be utilized for AE reporting. The CTCAE is identified and located on', 'the CTEP website at:', 'All appropriate treatment areas should have access to a copy of the CTCAE. All reactions', 'determined to be \"reportable\" in an expedited manner must be reported using the Cancer', 'Therapy Evaluation Program Adverse Event Reporting System (CTEP-AERS).', 'For further information on the NCI requirements for SAE reporting, please refer to the \"NCI', \"Guidelines for Investigators: Adverse Event Reporting Requirements' document published by\", 'the NCI.', 'PRO-CTCAE data should not be used for determining attribution, or reporting of serious adverse', 'events.', 'Note: All deaths on study require both routine and expedited reporting regardless of causality.', 'Attribution to treatment or other cause should be provided.', '32', 'NCI version date 8/14/2020', 'Update #03']\n\n###\n\n", "completion": "END"}